Q1 Earnings Forecast for BioNTech Issued By Leerink Partnrs

BioNTech SE (NASDAQ:BNTX) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of BioNTech in a research note issued on Monday, April 21st. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings of ($5.78) per share for the quarter. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. Leerink Partnrs also issued estimates for BioNTech’s Q2 2025 earnings at ($2.70) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at ($9.20) EPS, FY2026 earnings at ($3.87) EPS, FY2027 earnings at ($2.62) EPS, FY2028 earnings at ($1.79) EPS and FY2029 earnings at ($0.63) EPS.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the previous year, the company earned $1.90 earnings per share. The company’s revenue was down 19.5% compared to the same quarter last year.

Other analysts have also recently issued research reports about the company. Citigroup initiated coverage on BioNTech in a research report on Thursday, March 13th. They issued a “buy” rating and a $145.00 price target for the company. BMO Capital Markets upped their target price on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. HC Wainwright dropped their price target on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Morgan Stanley decreased their price objective on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $143.44.

BioNTech Stock Up 2.8 %

BNTX stock opened at $104.68 on Wednesday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $25.12 billion, a PE ratio of -49.85 and a beta of 1.07. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a fifty day simple moving average of $102.22 and a 200 day simple moving average of $110.75.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BNTX. Jones Financial Companies Lllp boosted its holdings in BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its position in shares of BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after buying an additional 700 shares during the period. Allianz SE acquired a new stake in BioNTech in the 4th quarter valued at $90,000. GAMMA Investing LLC grew its position in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after acquiring an additional 300 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new position in BioNTech during the fourth quarter worth $137,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.